GSK, Celgene cough up milestone payments

Share this article:

Epizyme announced Monday that its experimental orphan drug for acute leukemia, EPZ-5676, achieved its proof-of-concept milestone, triggering a $25-million payment from partner Celgene. The drug is for patients in whom the MLL gene is rearranged due to a chromosomal translocation or partial tandem duplication. The conditions result in “an increased expression of genes causing leukemia.”

The Cambridge, MA, company also scored $4 million from partner GlaxoSmithKline for a milestone payment associated with one of three histone methyltrasferase targets. The companies joined up in 2011 for a deal that includes up to $626 million in milestone payments and sales-based milestone payments of up to $270 million.

Share this article:

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.